Drug Trial Radar · NCT03025945
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
Last checked: Nov 20, 2026Latest source record: Dec 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
662
Actual
Start
Oct 2013
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- Intuor Technologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.
Conditions
- Cystoid Macular Edema
Interventions
Nepafenac 0.3%Drug
Saline SolutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-operative Clinical Findings of Cystoid Macular EdemaTime frame: 6 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.